APS Annual Meeting at Experimental Biology



Identifying and Validating Novel Autonomic Targets for Treating Cardiovascular Diseases

Symposium — Thursday, April 29, 2021 — 4:00 PM - 5:30 PM — , Room APS-13
Neural Control and Autonomic Regulation Section — Chair: David J Paterson — Co-Chair: Julian J Paton

Over the last decade, there has been a boom in tool and technology development that has created new opportunities for physiologists understanding disease process in autonomic control of the cardiovascular system. We wish to propose a symposium on the enormous progress made using transcriptomics in the identification of druggable targets for future molecular therapeutic exploitation. Given the substantial investment the NIH has made towards the stimulation of peripheral areas to relieve conditions (e.g. the SPARC programme), it is clear that autonomic modulation is in vogue. The recent flurry of interventional clinical studies targeting the visceral-autonomic axis as a treatment strategy for chronic diseases in human patients further confirms the current interest in this field. Moreover, the COVID-19 pandemic and evidence of autonomic neuron infection and dysregulation is further testament to the research underpinning this proposed symposium. Our proposal is based on both trawling and validating novel autonomic targets for modulation in cardiovascular and respiratory diseases. To embellish this subject comprehensively we have assembled four speakers. Two are established, world renowned high profile scientists whereas the others are very impressive early career speakers, who we see as having potential for tomorrow’s leaders. We have a 50-50 gender split in speakers who cover Europe, America and Asia-Pacific regions. We wish to demonstrate the different techniques employed, the necessary validation approaches and translation during the symposium. We believe the symposium will attract a range of scientists from those interested in transcriptomics, proteomics, molecular biology, cell biophysics, G-protein coupled receptors, in vitro and in vivo systems physiology/patho-physiology, and translation to first in human clinical studies. All speakers will all report on their distinct approaches for identifying novel molecular targets within different components of the visceral afferent-autonomic nervous system axis. They will demonstrate how these targets are validated, their cellular locality and how they have been modulated to either rescue or ameliorate cardiovascular dysfunction in both animal models of disease and their human counterparts. Our speakers will talk on cardiovascular sensors including carotid body chemoreceptors (Audrys Pauza) and arterial baroreceptors (Mark Chapleau), while Beth Habecker and Emma Bardsley will speak on the stellate ganglia and sympathetic-cardiac transmission in health and disease. All speakers will update on human studies and resultant clinical trials where appropriate. Following the cancellation of EB 2020, we contacted all participants and they have confirmed their continued interest and availability to present in our symposium for EB 2021. Over the lasts 7 years Professors Paterson and Paton have organized numerous symposia at previous Experimental Biology conferences and in all cases they have been very well attended and accompanied with excellent positive feedback. Given the topicality of the techniques and subject matter of the proposed symposium, we have no reason to doubt that this symposium will also be well attended.

Speakers

  • TrkA modulation after myocardial infarction restores sympathetic nerves and cardiac function
    Beth Habecker — Physiology and Pharmacology, Oregon Health & Science University

  • Transcriptomic differences in the rat hypertensive carotid body: revealing novel targets
    Audrys Pauza — Physiology, Pharmacology & Neuroscience, University of Bristol

  • AngII-ACE2 pathway in stellate ganglia: implications for neural control of cardiac excitability
    Emma Bardsley — Physiology, University of Auckland

  • Piezo Channels Mediate Baroreceptor Mechanosensory Transduction: Functional and Therapeutic Implications
    Mark Chapleau — Internal Medicine, University of Iowa




Host Societies

Copyright © 2021 Experimental Biology (EB) | Experimental Biology® is a federally registered trademark of EB.